Kronos Bio Inc
Change company Symbol lookup
Select an option...
KRON Kronos Bio Inc
GOVT iShares U.S. Treasury Bond ETF
BAC Bank of America Corp
$NQASPA50JPYN Nasdaq ASPA Industrials Net Total Re
SNP China Petroleum & Chemical Corp
GAEC Gulf Alternative Energy Corp
RDBX Redbox Entertainment Inc
AFG American Financial Group Inc
MRNA Moderna Inc
PFE Pfizer Inc
Go

Health Care : Biotechnology |
Company profile

Kronos Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of cancer therapeutics designed to target dysregulated transcription. Its product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks (TRNs) that drive their oncogenic activity. Its lead product candidate, entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase (SYK) inhibitor that is being developed for the treatment of acute myeloid leukemia (AML). Its second product candidate, KB-0742, is generated from its product engine’s small molecule microarray (SMM) platform. KB-0742 is designed to be an orally bioavailable inhibitor of CDK9 with a differentiated selectivity profile. Its KB-0742 is in advanced solid tumors with MYC genomic copy number gain (amplification).

Closing Price
$12.29
Day's Change
-0.81 (-6.18%)
Bid
--
Ask
--
B/A Size
--
Day's High
13.74
Day's Low
12.29
Volume
(Average)
Volume:
213,815

10-day average volume:
220,047
213,815
  • Prev Close
    13.10
  • Today's Open
    12.60
  • Day's Range
    12.29-13.74
  • Avg Vol (10-day)
    220.0K
  • Last (time)
    1:00p ET 11/26/21
  • Last (size)
    50
  • 52-Wk Range
    12.29 - 38.98
    LowHigh
  • (12/22/20 - 11/26/21)
    0.00%
  • 58.8%
  • Market Cap
    692.5M
  • Shares Outstanding
    56.3M
  • -2.21
  • --
  • No dividend
  • Ex-dividend Date
    No dividend
  • Dividend Pay Date
    No dividend
  • --
  • 66.70
  • (% of float 11/15/21)
    10.97

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2021. All rights reserved.